Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,002 public trials 569 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Active, Not Recruiting

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

NCT05014646

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Atrium Health University City/LCI-University Charlotte, North Carolina, United States
View Trial Details
Active, Not Recruiting

PRospective Multiple Myeloma Impact Study

NCT02911571

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Lombardi Comprehensive Cancer Center Washington D.C., District of Columbia, United States
  • Winship Cancer Institute, Emory University Atlanta, Georgia, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • New York Presbyterian Brooklyn Methodist Hospital Brooklyn, New York, United States
View Trial Details
Active, Not Recruiting

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

NCT04960579

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Goodyear, Arizona, United States
  • University of California San Diego San Diego, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Emory University Atlanta, Georgia, United States
View all 23 locations
View Trial Details
Active, Not Recruiting

Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT06868667

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Aomori, Japan
  • GSK Investigational Site Fukuoka, Japan
  • GSK Investigational Site Himeji, Japan
  • GSK Investigational Site Kamakura, Japan
View all 16 locations
View Trial Details
Active, Not Recruiting

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT04246047

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Yuma, Arizona, United States
  • GSK Investigational Site Denver, Colorado, United States
  • GSK Investigational Site Kansas City, Kansas, United States
  • GSK Investigational Site Fairfield, Ohio, United States
View all 69 locations
View Trial Details

Related conditions